Inotrem: Funding, Investors & Team (Sep 2026)
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.
Inotrem has raised $53.4M across 3 funding rounds on record, the most recent an undisclosed round announced in Nov 2023.
Inotrem Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Inotrem Funding Rounds
2 of 3 rounds were announced without a disclosed amount and are excluded from the total.
Inotrem raised $53.4M in a Debt Financing announced in Jul 2021.
1.5 years later, an undisclosed round was announced in Jan 2023 with no disclosed amount.
10 months later, an undisclosed round was announced in Nov 2023 with no disclosed amount.
Inotrem Founders and Leadership Team
Contact details for the Inotrem team: 1 of 2 have an email address on file.
Start 14-day free trial →Inotrem Funding Compared to Other Biotechnology Startups
Funded Startups Like Inotrem in Biotechnology and Paris
Companies Similar to Inotrem
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Inotrem Funding FAQs
What does Inotrem do?
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.
How much funding has Inotrem raised?
Inotrem has raised $53.4M across 3 rounds on record.
When did Inotrem last raise funding?
Inotrem's most recent funding round on record was announced in Nov 2023. The amount was not disclosed.
Who founded Inotrem?
FundedIQ lists Marc Derive (Founder) at Inotrem.
Who is the CEO of Inotrem?
Sven Zimmermann is listed as CEO at Inotrem.
Where is Inotrem headquartered?
Inotrem is based in Paris, Ile-De-France, France.
How many employees does Inotrem have?
Inotrem is in the 11-50 employee band.
About FundedIQ's Inotrem Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Inotrem is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.